Back to top
more

Theravance Biopharma (TBPH)

(Delayed Data from NSDQ)

$8.74 USD

8.74
541,902

-0.11 (-1.24%)

Updated May 20, 2022 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.08%
2Buy18.56%
3Hold10.15%
4Sell5.79%
5Strong Sell2.83%
S&P50011.24%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (147 out of 253)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Income Statements

Research for TBPH

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year end for Theravance Biopharma, Inc falls in the month of December .

All items in Millions except EPS data.

12/31/21 12/31/20 12/31/19 12/31/18 12/31/17
Sales 55 72 73 60 15
Cost Of Goods 0 0 0 1 6
Gross Profit 55 72 73 60 9
Selling & Adminstrative & Depr. & Amort Expenses 313 370 325 298 269
Income After Depreciation & Amortization -258 -298 -252 -239 -260
Non-Operating Income 105 56 42 23 -3
Interest Expense 47 45 32 10 9
Pretax Income -200 -287 -242 -226 -272
Income Taxes 0 -9 -5 -11 14
Minority Interest 0 0 0 0 0
Investment Gains/Losses 0 0 0 0 0
Other Income/Charges 0 0 0 0 0
Income From Cont. Operations -199 -278 -236 -216 -285
Extras & Discontinued Operations 0 0 0 0 0
Net Income -199 -278 -236 -216 -285
Depreciation Footnote 12/31/21 12/31/20 12/31/19 12/31/18 12/31/17
Income Before Depreciation & Amortization -252 -292 -249 -236 -256
Depreciation & Amortization (Cash Flow) 6 6 3 3 4
Income After Depreciation & Amortization -258 -298 -252 -239 -260
Earnings Per Share Data 12/31/21 12/31/20 12/31/19 12/31/18 12/31/17
Average Shares 69.46 62.35 55.61 53.97 52.35
Diluted EPS Before Non-Recurring Items -2.87 -4.20 -4.25 -3.99 -5.45
Diluted Net EPS -2.87 -4.46 -4.25 -3.99 -5.45

Fiscal Year end for Theravance Biopharma, Inc falls in the month of December .

All items in Millions except EPS data.

3/31/22 12/31/21 9/30/21 6/30/21 3/31/21
Sales 13.20 14.95 13.19 12.91 14.26
Cost Of Goods 0.00 0.00 0.00 0.00 0.00
Gross Profit 13.20 14.95 13.19 12.91 14.26
SG&A, R&D, and Dept/Amort Expenses 51.70 71.12 66.81 77.02 98.15
Income After SG&A, R&D, and Dept/Amort Expenses -38.50 -56.17 -53.62 -64.11 -83.89
Non-Operating Income 24.74 35.64 30.04 23.10 16.31
Interest Expense 11.66 11.66 11.74 11.61 11.87
Pretax Income -25.42 -32.18 -35.32 -52.63 -79.45
Income Taxes 0.52 -0.15 -0.01 -0.22 0.23
Minority Interest 0.00 0.00 0.00 0.00 0.00
Investment Gains/Losses 0.00 0.00 0.00 0.00 0.00
Other Income/Charges 0.00 0.00 0.00 0.00 0.00
Income From Cont. Operations -25.95 -32.03 -35.31 -52.41 -79.68
Extras & Discontinued Operations 0.00 0.00 0.00 0.00 0.00
Net Income -25.95 -32.03 -35.31 -52.41 -79.68
Earnings Per Share Data 3/31/22 12/31/21 9/30/21 6/30/21 3/31/21
Average Shares 75.25 73.96 73.57 65.67 64.49
Diluted EPS Before Non-Recurring Items -0.24 -0.43 -0.48 -0.80 -1.24
Diluted Net EPS -0.34 -0.35 -0.48 -0.80 -1.24